Here's an interesting fact: companies that rely on data to make their decisions are more likely to achieve better results.

ADQ, an active sovereign investor focused on critical infrastructure and global supply chains, and the Gates Foundation today announced a landmark partnership to accelerate the responsible and ...

This summer, Yale New Haven Health hosted the Yale Robotic Surgery Symposium to celebrate the milestone of 30,000 robot-assisted surgeries. This milestone reflects the institution’s leadership in ...

An interactive toolbox for standardizing, validating, simulating, reducing, and exploring detailed biophysical models that can be used to reveal how morpho-electric properties map to dendritic and ...

Tzeract and kwiff share their insights on the innovation behind Flex with SBC News and what it means for the future of sports ...

NEW YORK, Dec. 10, 2025 /PRNewswire/ -- Breast cancer remains one of the most common cancers in the world — but advances in screening, diagnostic tools, and personalized treatment are transforming how ...

This important study combines optogenetic manipulations and wide-field imaging to show that the retrosplenial cortex controls behavioral responses to whisker deflection in a context-dependent manner.

Parallel Learning, a virtual special education platform, secured $20 million in Series B funding to address critical nationwide special education teacher shortages and resource gaps. The company ...

SAN CARLOS, Calif.--(BUSINESS WIRE)--$ONC #BeOne--BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data on ...

Microsoft chief executive Satya Nadella on Wednesday said that the winners of the global AI race will be determined by how quickly countries and companies adopt the technology rather than who invents ...

REDWOOD CITY, Calif., Dec. 08, 2025 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. (NASDAQ: CHRS) today announced compelling six-year overall survival (OS) follow-up results from the Phase 3 JUPITER-02 ...

- Financing accelerates development of lead candidate AV078, a CNS-penetrant selective mTORC1 inhibitor, and will fund completion of its Phase 2 clinical trial - Round co-led by Luma Group and CTI ...